# Hittegolf bij hartfalen: fenotype-gedreven bewaking en individuele medicatie-aanpassing

*geplaatst 2026-11-18 · Hartfalen · Heart failure reviews · doi 10.1007/s10741-026-10695-3 · https://hartvaat.nl/2026/11/10/hittegolf-bij-hartfalen-fenotype-gedreven-bewaking-en-individuele-medicatie-aanp/*

Deze narratieve review belicht de verhoogde kwetsbaarheid van patiënten met hartfalen tijdens hittegolven, waarbij hitte de cardiovasculaire reserve verder beperkt en het risico op hypotensie, nierfunctieverlies en elektrolytstoornissen verhoogt. Hoewel observationele studies een verband laten zien met meer mortaliteit, ontbreken RCT’s die richtlijnen geven voor het aanpassen van de GDMT. De auteurs pleiten voor een fenotype-gedreven aanpak: hitte-alarmen moeten leiden tot verhoogde alertheid en patiënteducatie, maar medicatie-aanpassingen moeten uitsluitend worden bepaald door symptomen, vochtstatus, bloeddruk en nierfunctie, niet door de buitentemperatuur alleen. Dit voorkomt automatische medicatie-afbouw en verbetert de klinische vigilantie tijdens extreme weersomstandigheden.

## English: Heatwaves in HF: From risk to clinical action.

This narrative review highlights the heightened vulnerability of heart failure patients during heatwaves, as heat dissipation demands cutaneous vasodilation that further strains an already limited cardiovascular reserve, increasing risks of hypotension, renal impairment, and electrolyte disturbances. While observational data link high temperatures to increased cardiovascular mortality, no randomized trials currently guide guideline-directed medical therapy adjustments. The authors advocate a phenotype-driven approach where heat alerts trigger enhanced surveillance and patient education, but medication changes should be driven by congestion, blood pressure, renal function, and symptoms rather than ambient temperature alone. This strategy prevents automatic de-escalation of heart failure therapies and emphasizes targeted clinical vigilance during extreme heat events.

## Abstract (original, from the publication)

Extreme heat represents an important clinical challenge for patients with cardiovascular disease (CVD). Individuals with heart failure (HF) may be particularly vulnerable because heat dissipation requires cutaneous vasodilation, increased skin blood flow, and sweating, whereas HF may limit cardiovascular reserve and increase susceptibility to hypotension, renal dysfunction, and electrolyte disturbances. Risk is further amplified by advanced age, chronic kidney disease (CKD), frailty, cognitive impairment, limited access to cooling, and the use of medications that influence volume status, blood pressure (BP), or thermoregulation. Observational evidence links high ambient temperatures with cardiovascular morbidity and mortality, and recent HF-specific data support an association between short-term heat exposure and increased mortality. However, evidence directly guiding the clinical management of chronic HF during heatwaves remains limited. No randomized controlled trial (RCT) has established whether or how guideline-directed medical therapy (GDMT) should be modified solely in response to hot weather. This focused narrative review proposes a cautious, phenotype-driven approach. Local heat alerts should prompt anticipatory risk assessment, patient education, and temporary intensification of surveillance, whereas treatment changes should be determined by the interaction between symptoms, congestion, BP, weight, oral intake, urine output, renal function, and electrolytes rather than ambient temperature alone. Telemonitoring may provide an enabling infrastructure for this strategy, although heat-alert-triggered remote management has not been prospectively validated. Extreme heat should therefore prompt increased clinical vigilance rather than automatic medication withdrawal. Prospective studies are needed to validate heat-specific monitoring pathways, hydration strategies, and medication-review protocols in chronic HF.

Auteurs: Antonio Luca Maria Parlati, Luca Martini, Cristina Madaudo

---
Bron: Heart failure reviews, https://doi.org/10.1007/s10741-026-10695-3. Bijgewerkt 2026-11-11T02:18:22Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.
